Capricor Therapeutics — Third Quarter 2026 Earnings Summary

Capricor Therapeutics reported a net loss of $42.7 million for the third quarter of 2026, with total operating expenses rising to $44.7 million due to pre-commercial activities and manufacturing scale-up. The company holds approximately $198.5 million in cash and marketable securities as of September 30, 2026, which is sufficient to fund operations for at least the next twelve months. Its Biologics License Application for Deramiocel to treat Duchenne muscular dystrophy is under FDA review with a PDUFA target date of November 22, 2026, following a major amendment that included two-year open-label extension data. Recent clinical updates show that patients switching from placebo to Deramiocel experienced a 76% slowing in upper limb decline, and the drug's cardiac results received the American Heart Association's Outstanding Research Award in Pediatric Cardiology.